Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Experimental Dermatology · 2026-04 · 35 (4)
DOI: 10.1111/exd.70242 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Experimental Dermatology, online erschienen am 27.03.2026. Verfasst von Rafaela de Moraes-Souza und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Division, La Paz University Hospital, Comunidad de Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Eczema, Hand Dermatoses, Pyrroles, Quinazolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chronic hand eczema (CHE) is associated with substantial functional impairment and reduced quality of life. Delgocitinib, a pan‐Janus kinase (JAK) inhibitor, has emerged as a promising topical treatment for CHE. A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical delgocitinib 20–30 mg/g compared with vehicle in patients with CHE. PubMed, Embase, Cochrane Library, ClinicalTrials.gov , EU CTR, and WHO ICTRP were searched up to 15 February 2026. The primary outcome was treatment success at week 16, defined as clear or almost clear skin with a ≥ 2‐point improvement on the Investigator's or Physician's Global Assessment (IGA/PGA). Secondary outcomes included treatment success at weeks 4 and 8, changes in Hand Eczema Symptom Diary (HESD) itch and pain scores, and safety outcomes. Relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Three publications reporting four RCTs involving 1154 patients were included, with 752 receiving delgocitinib and 402 receiving vehicle. At week 16, treatment success was significantly higher with delgocitinib (RR 3.17; 95% CI 1.78–5.65; p < 0.01), corresponding to an absolute risk difference of 16.9% and a number needed to treat (NNT) of 6 (95% CI 3–16). Similar results at weeks 4 and 8. Delgocitinib also led to significantly greater improvements in HESD itch and pain scores. No significant differences were found in overall adverse events (AEs), treatment‐related AEs, or serious AEs. Discontinuation due to AEs was lower in the delgocitinib group. Delgocitinib 20–30 mg/g demonstrated greater efficacy than vehicle and a favourable safety profile, supporting its use as a topical treatment for CHE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Division, La Paz University Hospital, Comunidad de Madrid, Madrid, Spain.
- Division of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
- Division of Medicine, Albert Einstein Israeli Faculty of Health Sciences, São Paulo, São Paulo, Brazil.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Division of Medicine, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
ORCID-Profile: Rafaela de Moraes-Souza, Francesco Piscazzi, Matheus Barros de Albuquerque, Yasmin Mesquita, Izadora Lapenda, Guillermo Servera-Negre
Zitieren
APA
de Moraes-Souza, R., Bornia, M. J. P., Chater, R. C., Piscazzi, F., de Albuquerque, M. B., Mesquita, Y., Lapenda, I., Servera-Negre, G., Hernández-Cano, N., Sarto, R., & Herranz-Pinto, P. (2026). Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Experimental Dermatology, 35(4). https://doi.org/10.1111/exd.70242
Vancouver
de Moraes-Souza R, Bornia MJP, Chater RC, Piscazzi F, de Albuquerque MB, Mesquita Y, et al. Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Experimental Dermatology. 2026;35(4). doi:10.1111/exd.70242
BibTeX
@article{deMoraesSouza2026,
author = {de Moraes-Souza, Rafaela and Bornia, Maria Júlia Pilau and Chater, Regina Chahine and Piscazzi, Francesco and de Albuquerque, Matheus Barros and Mesquita, Yasmin and Lapenda, Izadora and Servera-Negre, Guillermo and Hernández-Cano, Natalia and Sarto, Rubiana and Herranz-Pinto, Pedro},
title = {Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Experimental Dermatology},
year = {2026},
volume = {35},
number = {4},
doi = {10.1111/exd.70242}
}
EUVIMED